VIA Disc NP Pilot for Patients With Symptomatic Degenerated Discs

A Pilot Study Evaluating the Safety and Clinical Effectiveness of Nucleus Pulposus Allograft for Supplementation of Nucleus Pulposus Tissue in Patients With Symptomatic Degenerated Discs

VIA Disc NP is an allograph intended to supplement the nucleus pulposus tissue in degenerated intervertebral discs.

Study Overview

• Status: Active, not recruiting
• Conditions: Low Back Pain; Degenerative Disc Disease; Disc Degeneration
• Intervention / Treatment: Other: VIA Disc NP

Detailed Description

The study will include adult subjects, ages 18 years or older, with symptomatic lumbar intervertebral disc degeneration that is not adequately resolved by non-surgical standard care. For the purpose of the primary analysis, subjects are considered enrolled in the study once they have signed the informed consent.

Each subject will receive one injection per level and be evaluated for efficacy and safety during the 24 month observation period. The study is expected to be completed within 26 months, inclusive of enrollment and follow-up for all subjects.

Subjects will be evaluated at baseline and followed through 24 months to establish safety and efficacy of the treatment. The expected duration of subject participation from screening/enrollment through final follow-up is 104 weeks.

• Study Type: Interventional
• Enrollment (Anticipated): 35
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • California
    • Larkspur, California, United States, 94939
      • California Orthopedics and Spine
    • Santa Monica, California, United States, 90404
      • Source Health
    • Walnut Creek, California, United States, 94598
      • IPM Medical Group
  • Ohio
    • Cleveland, Ohio, United States, 44195
      • Cleveland Clinic
  • Oklahoma
    • Edmond, Oklahoma, United States, 73013
      • Clinical Investigations, LLC
  • Virginia
    • Richmond, Virginia, United States, 23235
      • Virginia iSpine

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

Eligibility for inclusion is evaluated on a site-specific basis based on each subject's medical, clinical, and radiographic presentation. In addition, for study consistency purposes, the MRI imaging will be submitted to Medical Metrics Imaging (MMI), a core lab, for independent review. MMI will review imaging of every subject to confirm radiographic inclusion criteria. The Medical Monitor will make the final determination for inclusion on all subjects based on review of the MRI relevant medical history and source documents.

1. Age 18 years or older;
2. Body mass index (BMI) < 35;
3. Documented diagnosis of moderate radiographic degeneration of up to 2 intervertebral discs from L1 to S1, with a suspected associated discogenic chronic low back pain;
4. Chronic LBP for ≥ 6 months;

5. Failed conservative care over the past 3 months of at least 2 conservative treatments including:

   1. oral pain medication [analgesics, steroids and/or non-steroidal anti-inflammatory drugs (NSAIDs)],
   2. structured physical therapy or exercise program prescribed by physical therapist, chiropractor provider or physician specifically for the treatment of low back pain, and
   3. epidural steroid injections and/or facet injections/selective nerve blocks;

6. An MRI demonstrating:

   1. 1 to 2 vertebral level involvement L1-S1;
   2. Modified Pfirrmann Grade 3-7;
   3. No modic changes or if changes ≤ 2;
7. Oswestry Disability Index (ODI) score at time of evaluation of ≥ 40 and ≤ 80 points;
8. Low back pain of Baseline Numeric Rating Scale (NRS) score of ≥ 6 on the 11-point scale;
9. No signs or symptoms of current infection;
10. Be able to give voluntary, written informed consent to participate and have signed an Informed Consent Form specific to this study;
11. Be willing and able to comply with all study procedures and availability for the duration of the study with a life expectancy of > 2 years.

Exclusion Criteria:

1. Known allergies to components of VIA Disc NP, Gentamicin, or Vancomycin;
2. Contraindications to the proposed sedation/anesthetic protocol;
3. Radicular pain greater than back pain by history or evidence of radicular pain or neurological deficit within the past 6 months. Radicular pain is defined as nerve pain following a dermatomal distribution and that correlates with nerve compression on imaging. Somatic referred pain is allowed;

4. Any of the following conditions at the index level:

   1. Contained disc protrusion >5 mm or disc extrusion, or spondylolisthesis >5 mm (lysis and degenerative);
   2. Seronegative spondyloarthropathy;
   3. Symptomatic spinal stenosis (moderate to severe in degree);
   4. Chronic facet syndrome;
   5. Spondylodiscitis;
   6. Bilateral spondylolysis;
   7. Current or history of osteoporotic or tumor-related vertebral body compression fracture;
   8. Previous lumbar spine fusion surgery or disc arthroplasty;
5. History of sacroiliac (SI) joint pain/injections during the past 3 months or SI joint fusion within the past two years;
6. Received chemonucleolysis or percutaneous treatment of the affected disc prior to the study;
7. History of epidural steroid injections within 1 week prior to study treatment;
8. Received any lumbar intradiscal treatment injection or procedure (e.g., methylene blue, dextrose, glucosamine, and chondroitin sulfate, or biacuplasty) and any nerve ablation procedures at the same or adjacent level (e.g., Basivertebral nerve ablation, dorsal ramus or sinovertebral nerve ablations). Discography and anaesthetic discography may be performed but must be done at least 2 weeks or more prior to the injection procedure;
9. Been a recipient of prior stem cell/progenitor cell therapy or other biological intervention (e.g., PRP) to repair the target intervertebral disc;
10. Severe motor deficit or cauda equina disorder based on investigator determination;
11. Diagnosis of any traumatic neurological disorders;
12. Severe diseases of any other major body system as judged by the investigator, including malignant diseases of any solid organ or any hematologic malignancy during the previous 5 years;
13. Demonstrate 3 or more Waddell's signs of Inorganic Behavior;
14. Any mental instability, bipolar disorders, post-traumatic stress disorder (PTSD) or uncontrolled anxiety/depression and/or require new or changed anti-depressants or anti-psychotic medications within 3 months of enrollment;
15. Compensated injuries or ongoing litigation regarding back pain/injury, or financial or other incentives to remain impaired;
16. If female and of child-bearing potential, are pregnant or breastfeeding or a plan to become pregnant or breastfeed in the first 12 months post-treatment;
17. Any medical condition that impairs follow-up (i.e., fibromyalgia, rheumatoid arthritis, chronic regional pain syndrome, reflex sympathetic dystrophy);
18. Evidence of substance abuse (including marijuana); Note: subjects using prescribed extended-release narcotics (e.g., fentanyl patch, MS Contin, oxycontin) within the 3 months prior to screening; subjects on long-acting opioids may be given option to wean off opiates before enrollment. Subjects on short-acting opiates (e.g., hydrocodone, oxycodone, tramadol, etc.) may be included and utilization monitored after the treatment;
19. Are currently receiving treatment with radiation, chemotherapy, immunosuppression, or chronic steroid therapy (prednisone, or its equivalent, use of up to 5 mg/qd is allowed, as well as inhalation steroids for asthma);
20. Active implantable devices, such as cardiac pacemakers, spinal cord stimulators, intrathecal pumps, etc.;
21. Bilateral spondylolysis at any level;
22. Fracture of the spine, previous lumbar spine surgery or previous treatment of the target disc.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: VIA Disc Nucleus Pulposus Allograft; A single dose, intradiscal injection of 100mg of VIA Disc NP mixed with 2ml sterile saline administered to the affected 1 or 2 levels, L1-S1.	Other: VIA Disc NP; VIA Disc NP is processed from donated cadaveric disc tissue, lyophilized, and micronized to particles.; Other Names: VIA Disc Nucleus Pulposus Allograft

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Patient self-reporting of Functional Efficacy with no change in neurological status using the Oswestry Disability Index (ODI)	Evaluate the change from baseline in functional disability on the Oswestry Disability Index (ODI) measured from 0 (minimal disability) to 100 (maximal disability). The ODI is 10 categories of function to quantify disability due to low back pain.	baseline to 3 months
Review of all Adverse Events for Safety of treatment and product	Evaluate the incidence of related Adverse Events (AEs), Serious Adverse Events (SAEs), and Unanticipated Adverse Events from baseline through the final follow-up visit that are related to treatment and product	baseline to 6 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Patient self-reporting of Pain	Changes in Numeric Rating Scale (NRS) scores. Eleven point pain scale used for patient self-reporting of back pain, which ranges from 0 (no pain) to 10 (the worst pain imaginable). Analysis at 3 and 6 months measured as subjects meeting lower back pain NRS improvement of 50%.	3-6 months
Patient self-reporting of Pain in low back	Changes in Numeric Rating Scale (NRS) scores. Eleven-point pain scale used for patient to self-report level of back pain, which ranges from 0 (no pain) to 10 (the worst pain imaginable). Analysis at 3 and 6 months measured as subjects meeting lower back pain NRS improvement of ≥30%.	3-6 months
Oswestry Disability Index (ODI) score change	Change from baseline in ODI scores at 6 months. Ten category index comprising of function to quantify due to low back pain. ODI is measured 0 (minimal disability) to 100 (maximal disability).	baseline and 6 months
Numeric Rating Scale change	Changes from baseline in Numeric Rating Scale (NRS) score at 3 and 6 months. Eleven-point pain scale used for patient self-reporting of pain, which ranges from 0 (no pain) to 10 (the worst pain imaginable).	baseline, 3 and 6 months
Patient self-reporting of Function	Owestry Disability Index (ODI) is measured 0 (minimal disability) to 100 (maximal disability). This index is comprised of ten categories of function to quantify disability due to low back pain. Functional responder analysis at 3 and 6 months measured as subjects meeting functional improvement of ≥ 10, 15 and 20 points in ODI scores.	3-6 months
Neurological status change	Change from baseline in motor function (graded 0 - no movement to 4 - active movement against resistance), reflexes (0 - absence to 4 - abnormal/hyperactive) and sensory status (graded normal or abnormal) based on physician's physical exam at 1, 3, and 6 months.	baseline to 6 months
Return to work	Patient reported return to work - same or different capacity responses to employment questions will be assessed across time points and compared.	baseline - 6 months
Magnetic Resonance Imaging (MRI) review to determine disc health changes	Magnetic Resonance Imaging (MRI) taken at baseline compared to 6 months reviewing changes in treated disc levels (disc height, volume hydration of disc and Modified Pfirrman grade)	baseline-6 months

Collaborators and Investigators

• Sponsor: VIVEX Biologics, Inc.
• Collaborators: MCRA
• Investigators: Principal Investigator: Douglas Beall, MD, Clinical Radiology of Oklahoma

Study record dates

Study Major Dates

• Study Start (Actual): December 30, 2021
• Primary Completion (Anticipated): March 31, 2024
• Study Completion (Anticipated): July 31, 2024

Study Registration Dates

• First Submitted: September 24, 2021
• First Submitted That Met QC Criteria: January 14, 2022
• First Posted (Actual): January 21, 2022

Study Record Updates

• Last Update Posted (Actual): April 10, 2023
• Last Update Submitted That Met QC Criteria: April 6, 2023
• Last Verified: April 1, 2023

More Information

Terms related to this study

• Keywords: low back pain; degenerative disc disease
• Additional Relevant MeSH Terms: Pain; Neurologic Manifestations; Musculoskeletal Diseases; Spinal Diseases; Bone Diseases; Back Pain; Low Back Pain; Intervertebral Disc Degeneration
• Other Study ID Numbers: VIA-2021-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No